AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera
11.5.2023 19:18:00 EEST | Business Wire | Press release
AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger from the Medical University of Vienna, Austria1 reported the findings in an abstract accepted for presentation at the prestigious EHA (European Hematology Association) 2023 Annual Meeting.
Link to CONTINUATION-PV Abstract.
Reducing the risk of thrombotic events is an important goal in the treatment of PV
The abstract accepted for presentation at the EHA 2023 Annual Meeting focused on the proportion of time individual patients spent with peripheral blood cells counts meeting the targets recommended to minimize thrombotic complications. This longitudinal analysis - an emerging method to assess thrombotic risk in PV - takes fluctuations of response over long-term treatment into account, which are not detectable in conventional analyses evaluating only a few distinct time points.
Professor Heinz Gisslinger from Vienna, first author of the paper stated that: “Results from the CONTINUATION-PV study have deepened our understanding of the benefits of long-term treatment with ropeginterferon alfa-2b, one of the few new treatments to become available for patients with PV in previous decades. This analysis demonstrates previously unknown differences between hematologic responses to ropeginterferon alfa-2b and best available treatment, which impact individual thrombotic risk.”
1 From snapshot to continuum: cumulative time in response as an emerging proxy for thrombotic risk in polycythaemia vera. Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, and Jean-Jacques Kiladjian for the PROUD-PV Study Group, European Haematology Association EHA, 28th Annual Meeting June 2023
About Polycythaemia Vera
Polycythaemia Vera (PV) is a rare cancer of the blood-building stem cells in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. This condition increases the risk for circulatory disorders such as thrombosis and embolism, its symptoms lead to a reduced quality of life and on the long run may progress to myelofibrosis or transform to leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to blood-building stem cells in the bone marrow with a set of acquired mutations, the most important being a mutant form of JAK2 that make up the malignant clone.
Important PV treatment goals are to achieve healthy blood counts (hematocrit below 45%), improve quality of life and to slow or delay the progression of disease.
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005430/en/
Contact information
Further inquiry
DI Isolde Fally
AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group
Isolde.Fally@aop-health.com
+43-676-500 4048
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates14.9.2026 16:40:00 EEST | Press release
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914150232/en/ Students from Qatar, Canada and Mexico during their visit to the University of Toronto as part of the Doha Debates Town Hall experience in Canada. (Photo: AETOSWire) An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives. This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of sp
Matt Shafer Joins Golub Capital as Head of Golub Equity Continuation Partners14.9.2026 16:30:00 EEST | Press release
Golub Capital (“the Firm”) today announced the appointment of Matt Shafer as Managing Director and Head of the Firm’s GP-led private equity secondaries strategy, Golub Equity Continuation Partners (“GECP”). In this role, he will be responsible for leading the continued growth and development of the strategy and helping expand the Firm’s equity investment capabilities. Matt will work closely with Greg Cashman, Vice Chair and Co-Head of Golub Capital’s Sponsor Finance practice, to expand Golub Capital’s activity in this growing market. Shafer brings nearly three decades of global experience as an investor, financier and advisor working with private equity firms. He was most recently Head of Capital Solutions and U.S. Private Equity at Northleaf Capital Partners. In this role, Shafer helped lead the firm’s private equity investment activities, including secondaries, co‑investments and structured capital. Prior to Northleaf, he was Partner and Head of Americas Private Equity at Vision Capi
HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI14.9.2026 16:19:00 EEST | Press release
AMRA Medical today announced an investment from HealthCap, one of Europe’s leading life science venture capital firms. This milestone marks a significant step in AMRA’s growth, underscoring market confidence in the company’s vision to transform the measurement and understanding of muscle and fat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914838191/en/ HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI HealthCap’s backing comes as quantitative MRI gains vital importance in understanding how fat distribution and muscle composition influence disease, treatment response, and patient outcomes. Built on over 15 years of research, AMRA’s proprietary methods move beyond conventional metrics—like weight, and BMI and muscle function tests—to provide the standardized, automated data from advanced muscle and fat imaging necessary for modern clinical research. With its deep scientific expertise and
Morgan Stanley Inclusive & Sustainable Ventures Announces 2026 Global Cohort of Innovators14.9.2026 16:00:00 EEST | Press release
Morgan Stanley (NYSE: MS) today announced the 2026 global cohort of its Inclusive & Sustainable Ventures (MSISV). This year’s cohort includes 20 startups and four nonprofits across the Americas and Europe, the Middle East and Africa (EMEA) participating in the firm's five-month accelerator program designed to help early-stage innovators develop and scale their impact. Selected from thousands of applications, the 24 organizations will receive a $150,000 equity investment, or grant funding for nonprofits, as well as access to a curated curriculum, networking opportunities and office space. Founders will work closely with a dedicated MSISV team, Entrepreneurs in Residence and senior Morgan Stanley mentors. Following the five-month accelerator program, the cohort will present at a global showcase and demo day in February 2027. MSISV is focused on advancing solutions in four thematic areas where the firm sees significant potential for scale and measurable impact: Environment, Health & Wellb
Textron Aviation and Merlin Introduce Cessna SkyCourier UX Concept Aircraft14.9.2026 15:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, and Merlin, Inc. today introduced a concept Cessna SkyCourier UX™ aircraft that combines Textron Aviation’s proven Cessna SkyCourier platform with Merlin’s aircraft-agnostic software solution for autonomous aviation. Revealed at the Air, Space & Cyber Conference, the concept explores a new cost-efficient and scalable approach to addressing logistical challenges with supplying forces dispersed across contested operational environments when traditional supply routes are constrained, vulnerable or otherwise unavailable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914611105/en/ The Cessna SkyCourier UX concept explores autonomous resupply operations for dispersed forces operating in contested environments “Military planners are increasingly focused on how to sustain forces across distributed and contested operational environments,” said Bob Gibbs, vice president, D
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom